ASCK
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
08/21/2025
Back to search
Official data from USPTO
JP JAZZ PHARMACEUTICALS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
15
Latest update
02/27/2026
Trademark type
Combined
Nice classes
5
Filing date
08/30/2024
Registration date
02/04/2025
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
02/04/2025
Last transaction
02/27/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
First use anywhere
06/07/2024
First use in commerce
06/07/2024
Drawing code
3
Owner type
99
Owner location
Dublin, IE
Examiner
STIGLITZ, SUSAN R
Law office
L90
Current location
FILE REPOSITORY (FRANCONIA)
Mark description
The mark consists of "JAZZ PHARMACEUTICALS" positioned to the right of a circular logo with a stylized depiction of the letters "JP" which vertically splits the circle.
Holders and representatives
Holders
Jazz Pharmaceuticals Ireland Limited
Representatives
Michael T. Olsen Winthrop & Weinstine, P.A.
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceuticals for the treatment and prevention of cancerpsychiatric diseases and disorderscentral nervous system conditionspainsleep disordersnarcolepsyschizophreniafor use in oncology and hematology; pharmaceutical products for the prevention and treatment of cancer; pharmaceutical preparations and substances for the treatment of psychiatric diseases and disorders; pharmaceutical preparations acting on the central nervous system; pain relief medication; pharmaceutical preparations for use in the treatment and/or management of sleep disorders; pharmaceutical preparations for the treatment of narcolepsy; pharmaceutical preparations for the treatment of schizophrenia; pharmaceutical preparations for use in oncology and hematology
Publications
History of USPTO decisions and trademark events.
15 publications found
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
02/04/2025
R.PR
REGISTERED-PRINCIPAL REGISTER
02/04/2025
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
12/17/2024
PUBO
PUBLISHED FOR OPPOSITION
12/17/2024
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
12/11/2024
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
11/22/2024
XAEC
EXAMINER'S AMENDMENT ENTERED
11/22/2024
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
11/22/2024
GNEA
EXAMINERS AMENDMENT E-MAILED
11/22/2024
CNEA
EXAMINERS AMENDMENT -WRITTEN
11/22/2024
DOCK
ASSIGNED TO EXAMINER
11/19/2024
MDSC
NOTICE OF DESIGN SEARCH CODE E-MAILED
11/10/2024
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
11/10/2024
NWAP
NEW APPLICATION ENTERED
08/30/2024
Continuous trademark protection
Get notified about every new filing that threatens JP JAZZ PHARMACEUTICALS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.